Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 3/20 | 0.55 |
| ▸ | BRD2 | P25440 | 1/20 | 0.55 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.55 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.55 |
| ▸ | HDAC6 | Q9UBN7 | 5/20 | 0.53 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.53 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.52 |
| ▸ | BCHE | P06276 | 2/20 | 0.50 |
| ▸ | ACHE | P22303 | 2/20 | 0.50 |
| ▸ | ALB | P02768 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14894238 | 0.87 | HDAC1 (0.56) | HDAC6HDAC1BCHEACHE | |
| SCHEMBL14896147 | 0.86 | HDAC6 (0.72) | HDAC6HDAC1 | |
| SCHEMBL14903172 | 0.85 | BRD4 (0.55) | BRD4BRD2BRD3CREBBPHDAC6 | |
| SCHEMBL14895937 | 0.84 | HDAC6 (0.75) | HDAC6HDAC1 | |
| SCHEMBL588 | 0.83 | BCHE (0.69) | BRD4BRD2BRD3CREBBPBCHE | |
| SCHEMBL14893720 | 0.82 | HDAC6 (0.53) | HDAC6HDAC1 | |
| SCHEMBL14896109 | 0.81 | HDAC6 (0.52) | HDAC6HDAC1 | |
| SCHEMBL20961446 | 0.81 | HDAC6 (0.76) | HDAC6HDAC1 | |
| SCHEMBL14895798 | 0.79 | BRD4 (0.53) | BRD4BRD2BRD3CREBBPBCHE | |
| SCHEMBL14896412 | 0.79 | HDAC6 (0.49) | HDAC6HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140315889-A1 | HYDROXAMATE DERIVATIVES FOR HDAC INHIBITOR, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THEREOF | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2014-10-23 | — | — | US | disclosed |
| US-20140315889-A1 | HYDROXAMATE DERIVATIVES FOR HDAC INHIBITOR, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THEREOF | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2014-10-23 | — | — | US | disclosed |
| EP-2771321-A1 | HYDROXAMATE DERIVATIVES FOR HDAC INHIBITOR, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THEREOF | Chong Kun Dang Pharmaceutical Corp. (KR) | 2014-09-03 | — | — | EP | disclosed |
| WO-2013062344-A1 | HYDROXAMATE DERIVATIVES FOR HDAC INHIBITOR, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THEREOF | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2013-05-02 | — | — | WO | disclosed |
| WO-2013062344-A1 | HYDROXAMATE DERIVATIVES FOR HDAC INHIBITOR, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THEREOF | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2013-05-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140315889-A1 | HYDROXAMATE DERIVATIVES FOR HDAC INHIBITOR, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THEREOF | HDAC1, HDAC5, HDAC3 | BRD4 84/4885BRD2 91/4885BRD3 75/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.